IND clearance for OXU-001
We are thrilled to announce the IND clearance for suprachoroidal OXU-001, supporting it’s advancement into a Phase 2 clinical trial for the treatment of patients with diabetic macular edema. Read More
For front page news
We are thrilled to announce the IND clearance for suprachoroidal OXU-001, supporting it’s advancement into a Phase 2 clinical trial for the treatment of patients with diabetic macular edema. Read More
Oxular is thrilled to sponsor ISU 2022 in Utrecht, The Netherlands, and introduce the Oxulumis® suprachoroidal microcatheter to leading uveitis specialists. Together with Marc D. de Smet, we will host a series of skill transfer labs and provide hands-on instruction for routine suprachoroidal drug administration using Oxulumis®. We look forward to seeing you all there.
Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021. It was a pleasure to share this update, with a specific focus on OXU-001, Oxular’s lead program investigating a long-lasting, suprachoroidally administered treatment for DME. You can read Tom’s presentation below. Play Previous Next